Search results
Results From The WOW.Com Content Network
Bisacodyl is an organic compound that is used as a stimulant laxative drug. It works directly on the colon to produce a bowel movement. It is typically prescribed for relief of episodic and chronic constipation and for the management of neurogenic bowel dysfunction, as well as part of bowel preparation before medical examinations, such as for a colonoscopy.
A colonoscopy is considered the best way to screen for colon cancer because it allows doctors to remove polyps — small growths in the colon — before they potentially turn cancerous.
Orally administered sodium picosulfate is generally used for thorough evacuation of the bowel, usually for patients who are preparing to undergo a colonoscopy. It takes 12–24 hours to work, since it works in the colon. [3] Abdominal cramps and diarrhea are normal effects of picosulfate and should be expected.
Laxatives vary as to how they work and the side effects they may have. Certain stimulant, lubricant, and saline laxatives are used to evacuate the colon for rectal and bowel examinations, and may be supplemented by enemas under certain circumstances. Sufficiently high doses of laxatives may cause diarrhea.
Dulcolax may refer to: Dulcolax, a trade name of bisacodyl, a stimulant laxative drug that increases bowel movement; Dulcolax Balance, a trade name of macrogol, an osmotic laxative; Dulcolax Stool Softener, a trade name of dioctyl sodium sulfosuccinate, a common ingredient in products such as laxatives
By the way, if you get a positive result with a FIT test, doctors would then recommend that you get a colonoscopy for a further workup, he says. Ultimately, Dr. Doubeni says that the findings show ...
The Cologuard Plus test is now approved for adults ages 45 and older who are at average risk for colorectal cancer (CRC). FDA approval was based on findings from the pivotal BLUE-C study, one of ...
None of the participants experienced a colon perforation due to colonoscopy. After 10 years, an intention-to-screen analysis showed a significant relative risk reduction of 18% in the risk of colorectal cancer (0.98% in the invited group vs. 1.20% in the usual-care group). The analysis showed no significant change in the risk of death from ...